NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
The Indian pharma market grew 9.8% YoY in May 2024 (versus 8.9% in April 2024 and 10.2% in May 2023). Chronic category remained the key growth driver, supported by recovery in Acute therapies.
Cardiac/Gastro-intestinal therapies registered healthy YoY growth of 12.0% each. Respiratory/Gynae/Neuro/Ant-diabetic underperformed IPM by 500bp/300bp/300bp/200bp in May 2024.
For the 12 months ending in moving annual turnover May 2024, IPM grew 7.4% YoY. This growth was led by price/new launches, which contributed 4.1%/2.9% YoY to overall growth over the same period. Volume growth remained muted on MAT basis.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
Oil India - Fortifying Growth Through Integrated Expansion: Yes Securities
Sep 27, 2024
Piramal Pharma - Focus On Margin Expansion: Systematix
Sep 26, 2024
Indian Pharma Market Posts 6.3% Revenue Growth In August
Sep 11, 2024
India Pharma - Pick-Up In Acute Therapies Supporting IPM Growth In July: Motilal Oswal
Aug 26, 2024
POPULAR